¹⁷⁷Lu-DOTATATE PRRT as promising new treatment approach in Recurrent Skull Base Phosphaturic Mesenchymal Tumor causing paraneoplastic oncogenic osteomalacia: a potential therapeutic application of PRRT beyond NET

Abstract

The potential of peptide receptor radionuclide therapy (PRRT) is described in recurrent inoperable phosphaturic mesenchymal tumor involving left basi-occiput causing tumor-induced osteomalacia (TIO), for which the patient had undergone two times surgery previously. Following one cycle of PRRT, there was good symptomatic improvement, modest reduction of uptake on both ⁶⁸Ga-DOTATATE PET/CT and FDG-PET/CT suggesting favourable response and hence was considered for second cycle. Being somatostatin receptor avid, this rare group of tumors when inoperable or recurrent may be potentially targeted with PRRT. Well-tolerated and non-invasive, PRRT could evolve as a promising targeted treatment approach in this clinical setting. In summary, TIO with ⁶⁸Ga-DOTATATE avid inoperable/recurrent tumor can be considered as a potential and novel clinical treatment application of PRRT beyond neuroendocrine tumors.